Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Robert Salzman

Nurse Practitioner Tampa, FL Nurse Practitioner

NPI 1629686845 CMS profile 10946442

2002 N Lois Ave, Tampa, FL 33607

Open in the dashboard

General payments

$6,344

314 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Salzman of Tampa, FL is reported in the CMS Open Payments database as having received $6,344 across 314 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,999 147
2024 General $2,348 110
2023 General $997 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Salzman
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Robert Salzman were reported at $2,999. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Robert Salzman Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $997 $166 $54–$529 $160
2024 $2,348 $173 $55–$556 $164
2025 $2,999 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Regeneron Healthcare Solutions, Inc. $1,080 60 payments
  2. CSL Behring $1,014 69 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $905 45 payments
  4. AstraZeneca Pharmaceuticals LP $844 24 payments
  5. Genzyme Corporation $595 27 payments
  6. Novartis Pharmaceuticals Corporation $277 14 payments
  7. GlaxoSmithKline, LLC. $242 12 payments
  8. Pharming Healthcare, Inc. $179 8 payments
  9. Pfizer Inc. $138 7 payments
  10. BioCryst US Sales Co., LLC $117 6 payments
  11. Other $953 42 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $5,890 305 payments
  2. Education $429 8 payments
  3. Consulting Fee $25 1 payment
Products named General payments · program years 2023–2025
  1. DUPIXENT Immunology $793 37 payments
  2. DUPIXENT Inflammation And Immunology $561 35 payments
  3. DUPIXENT Immunology And Inflammation $519 25 payments
  4. Haegarda $498 35 payments
  5. CUVITRU $473 21 payments
  6. TAKHZYRO $377 22 payments
  7. AIRSUPRA $357 8 payments
  8. Andembry $306 17 payments
  9. FASENRA $284 9 payments
  10. Hizentra $210 17 payments
  11. Other $2,195 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

193

Median for Nurse Practitioner: 389

Drug cost

$33,746

Median for Nurse Practitioner: $21,885

Branded share of claims

36.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 22 $16,205
Breo Ellipta Fluticasone/Vilanterol Brand 20 $11,469
Symbicort Budesonide/Formoterol Fumarate Brand 12 $3,828
Azelastine Hcl Generic 17 $684
Albuterol Sulfate Hfa Albuterol Sulfate Brand 16 $395
Ipratropium Bromide Generic 15 $358
Fluticasone Propionate Generic 35 $314
Montelukast Sodium Generic 44 $259
Azithromycin Generic 12 $234

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$2,059

Medicare's payments for the services billed

Medicare patients

28

Average age 71

Services billed

254

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 64%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $434
  • GENZYME CORPORATION $177
  • SANOFI-AVENTIS U.S. LLC $99
$710 — —
Haegarda
  • CSL Behring $250
$250 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $241
$241 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $214
$214 — —
TAKHZYRO
  • Takeda Pharmaceuticals U.S.A., Inc. $197
$197 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

314 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record